Advertisement

FDA Approves Brentuximab Vedotin With Lenalidomide and Rituximab for Relapsed or Refractory LBCL


Advertisement
Get Permission

The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL)—including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma—after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or chimeric antigen receptor (CAR) T-cell therapy.

ECHELON-3

Approval was based on ECHELON-3 (ClinicalTrials.gov identifier NCT04404283), a randomized, double-blind, placebo-controlled trial which enrolled 230 adult patients with relapsed or refractory LBCL who were ineligible to receive auto-HSCT or CAR T-cell therapy. Patients were randomly assigned 1:1 to receive brentuximab vedotin plus lenalidomide and rituximab (BV+R2) or placebo plus lenalidomide and rituximab (Pbo+R2) until disease progression or unacceptable toxicity.

The major efficacy outcome measure was overall survival; additional efficacy outcome measures included progression-free survival and objective response rate per 2014 Lugano Criteria. The trial demonstrated a statistically significant overall survival improvement, with a median overall survival of 13.8 months (95% confidence interval [CI] = 10.3–18.8 months) in the BV+R2 arm and 8.5 months (95% CI = 5.4–11.7 months) in the Pbo+R2 arm (hazard ratio [HR] = 0.63, 95% CI = 0.45–0.89; P = .0085). The trial also demonstrated a statistically significant improvement in progression-free survival and objective response rate. Median progression-free survival was 4.2 months (95% CI = 2.9–7.1 months) with BV+R2 and 2.6 months (95% CI = 1.4–3.1 months) with Pbo+R2 (HR = 0.53, 95% CI = 0.38–0.73; P < .0001). The objective response rate was 64.3% (95% CI = 54.7%–73.1%) and 41.5% (95% CI = 32.5%–51.0%), respectively.

Adverse Reactions

The most common adverse reactions (occurring in ≥ 20% of patients)—excluding laboratory abnormalities in the BV+R2 arm—were fatigue, diarrhea, peripheral neuropathy, rash, pneumonia, and COVID-19 infection. Grade 3 to 4 laboratory abnormalities occurring in more than 10% of patients were decreased neutrophils, decreased lymphocytes, decreased platelets, and decreased hemoglobin. Peripheral neuropathy developed or worsened in 27% of patients, was predominantly sensory, and led to brentuximab vedotin dose reduction in 6% and discontinuation in 4.5%. 

The recommended brentuximab vedotin dose is 1.2 mg/kg up to a maximum of 120 mg in combination with lenalidomide and rituximab administered every 3 weeks until disease progression or unacceptable toxicity.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
Advertisement

Advertisement




Advertisement